AbbVie has selected North Carolina as the site for a new $1.4 billion manufacturing campus that will integrate artificial intelligence with advanced production and laboratory technologies to support its immunology, neuroscience, and oncology medicine lines. No timeline for completion was announced. The investment reflects both the scale of AbbVie’s pipeline ambitions and a broader pharmaceutical industry trend toward AI-assisted manufacturing—applying machine learning to process optimization, quality control, and yield prediction in ways that reduce variability and regulatory risk.

Cognizant and OpenAI have announced a partnership to deploy AI-powered software engineering, modernization, and security compliance capabilities—built on OpenAI’s Codex—to enterprise clients across industries. The collaboration targets complexity reduction, faster delivery cycles, and the governance structures required for enterprise-grade adoption. The partnership is a textbook play for both parties. For OpenAI, Cognizant’s client base of large enterprises across financial services, healthcare, manufacturing, and retail provides distribution at a scale that direct sales cannot easily replicate—and each enterprise deployment generates the usage data and feedback loops that sharpen the models.

The architecture of robot software has changed more in the past two years than in the previous two decades. The transition from task-specific modular systems to unified foundation models is not incremental improvement. It is a different approach to what a robot fundamentally is. The GAO’s 2026 S&T report documents this shift with precision. The previous generation of robot software divided cognition into pipeline stages: a perception module processed sensor input, a planning module generated action sequences, an actuation module executed them.